Table 1.
Characteristics of patients with unresectable hepatocellular carcinoma treated with sorafenib
| Characteristics | All (n = 13) |
|---|---|
| Age, (years), median [range] | 73 [62–81] |
| Gender (male/female), n | 11/2 |
| Etiology (HBV/HCV/NBNC), n | 3/4/6 |
| ECOG PS (0/1), n | 7/4 |
| Platelets (104/μL), median [range] | 11.2 [5.4–30.1] |
| M2BpGi (C.O.I) [range] | 2.51 [0.44–14.6] |
| Child‐Pugh score (5/6), n | 6/7 |
| ALBI Grade (1/2/3), n | 0/13/0 |
| Number of intrahepatic lesions (None/1/2–7/>7) | 0/1/8/3 |
| Maximum size of intrahepatic lesion (None/≤50/>50) (mm) | 0/10/3 |
| Portal vein invasion (absent/present), n | 10/3 |
| Extrahepatic spread (absent/present), n | 11/2 |
| AFP (ng/mL), median [range] | 104 [1–487 300] |
| AFP≧400 (yes/no) | 5/8 |
| BCLC stage (B/C), n | 9/4 |
| Previous treatment times of TAE/TACE [range] | 1 [0–4] |
| Initial dose of sorafenib (800/400), (mg), n | 3/10 |
AFP, alpha fetoprotein; ALBI, albumin‐bilirubin; BCLC, Barcelona Clinic Liver Cancer stages; ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCV, hepatitis C virus; M2BPGi mac‐2 binding protein glycosylation isomer; NBNC, non‐B non‐C; TACE, transcatheter arterial chemoembolization; TAE, transcatheter arterial embolization.